ReviewGene therapy2000
Gene therapy in the CNS.
Review in Gene therapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 141 citations in OpenAlex.
- AAV8 vector induced gliosis following neuronal transgene expression.Frontiers in neuroscience · 2024Article
- Gene modification therapies for hereditary diseases in the fetus.Prenatal diagnosis · 2023Review
- Crossing the blood-brain barrier with AAV vectors.Metabolic brain disease · 2021Review
- Dual-Modified Liposome for Targeted and Enhanced Gene Delivery into Mice Brain.The Journal of pharmacology and experimental therapeutics · 2020Article
- Bovine Herpesvirus-4-Vectored Delivery of Nipah Virus Glycoproteins Enhances T Cell Immunogenicity in Pigs.Vaccines · 2020Article
- MRI-Guided Focused Ultrasound for Targeted Delivery of rAAV to the Brain.Methods in molecular biology (Clifton, N.J.) · 2019Article
- Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties.International journal of nanomedicine · 2019Article
- Viral vectors for therapy of neurologic diseases.Neuropharmacology · 2017Review
- Comparative study of the transfection efficiency of commonly used viral vectors in rhesus monkey (Zoological research · 2017Article
- Article
- Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells.Cancer biology & therapy · 2014Article
- Neuronal uptake of nanoformulated superoxide dismutase and attenuation of angiotensin II-dependent hypertension after central administration.Free radical biology & medicine · 2014Article
- Antioxidant-based therapies for angiotensin II-associated cardiovascular diseases.American journal of physiology. Regulatory, integrative and comparative physiology · 2013Review
- Systemic delivery of scAAV9 in fetal macaques facilitates neuronal transduction of the central and peripheral nervous systems.Gene therapy · 2013Article
- Conditional gene expression systems in the transgenic rat brain.BMC biology · 2012Article
- Transcription factor Phox2 upregulates expression of norepinephrine transporter and dopamine β-hydroxylase in adult rat brains.Neuroscience · 2011Article
- Article
- Lentiviral vectors in gene therapy: their current status and future potential.Archivum immunologiae et therapiae experimentalis · 2010Review
- Investigation of molecular mechanism of chronic pain in the anterior cingulate cortex using genetically engineered mice.Current genomics · 2010Article
- Hybrid baculovirus-adeno-associated virus vectors for prolonged transgene expression in human neural cells.Journal of neurovirology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Gene therapy for neurological disorder is currently an experimental concept. The goals for clinical utilization are the relief of symptoms, slowing of disease progression, and correction of genetic abnormalities. Experimental studies are realizing these goals in the development of gene therapies in animal models. Discoveries of the molecular basis of neurological disease and advances in gene transfer systems have allowed focal and global delivery of therapeutic genes for a wide variety of CNS disorders. Limitations are still apparent, such as stability and regulation of transgene expression, and safety of both vector and expressed transgene. In addition, the brain adds several challenges not seen in peripheral gene therapy paradigms, such as post-mitotic cells, heterogeneity of cell types and circuits, and limited access. Moreover, it is likely that several modes of gene delivery will be necessary for successful gene therapies of the CNS. Collaborative efforts between clinicians and basic researchers will likely yield effective gene therapy in the CNS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.